Editorial
Dysregulation of the epigenetic regulator SETDB1 in liver carcinogenesis—more than one way to skin a cat
Chinese Clinical Oncology
2016;
5
(6)
:72
.
(27 December 2016)
SETDB1 is a new promising target in HCC therapy
Chinese Clinical Oncology
2016;
5
(6)
:73
.
(27 December 2016)
Molecular features of response to anti-PD-1 therapy
Chinese Clinical Oncology
2016;
5
(6)
:74
.
(27 December 2016)
Resistance patterns to anti-PD-1 therapy in metastatic melanoma
Chinese Clinical Oncology
2016;
5
(6)
:75
.
(27 December 2016)
Original Article
Metallothionein 2A an interactive protein linking phosphorylated FADD to NF-κB pathway leads to colorectal cancer formation
Chinese Clinical Oncology
2016;
5
(6)
:76
.
(27 December 2016)
A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation
Chinese Clinical Oncology
2016;
5
(6)
:77
.
(27 December 2016)
An efficient method for native protein purification in the selected range from prostate cancer tissue digests
Chinese Clinical Oncology
2016;
5
(6)
:78
.
(27 December 2016)
Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study
Chinese Clinical Oncology
2016;
5
(6)
:79
.
(27 December 2016)
Statistics in Oncology Clinical Trials1
Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the power of pooled individual patient data from multiple clinical trials
Chinese Clinical Oncology
2016;
5
(6)
:80
.
(27 December 2016)
Perspective
Does hepatitis B virus infection cause breast cancer?
Chinese Clinical Oncology
2016;
5
(6)
:81
.
(27 December 2016)
That’s how you make drugs!
Chinese Clinical Oncology
2016;
5
(6)
:82
.
(27 December 2016)
Meet the Professor2
Professor Charles M. Balch: higher sophistication and accuracy of clean data are important for sophisticated clinical trials
Chinese Clinical Oncology
2016;
5
(6)
:83
.
(27 December 2016)
Professor I. Craig Henderson: triple negative breast cancer is most chemo-sensitive of all subtypes of cancer
Chinese Clinical Oncology
2016;
5
(6)
:84
.
(27 December 2016)
Disclosure:
1. The series “Statistics in Oncology Clinical Trials” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Daniel J. Sargent and Qian Shi served as the unpaid Guest Editors for the series.
2. The series “Meet the Professor” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding.
